”This drug can do something different and much better”
Novo Nordisk’s science chief calls last week’s announcement concerning positive clinical results for the company’s oral diabetes drug “a milestone” and “a pioneering achievement” – and there is more news within the news, he says.
BY STEFAN SINGH KAILAY
Last Friday was a special day for Mads Krogsgaard Thomsen, as Novo Nordisk’s Chief Scientific Officer could announce to the market that the company has succeeded in showing efficacy from a large protein in an oral formulation.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo’s handpicked dozen to decide Tresiba’s fate
For abonnenter
Novo Nordisk CEO: “We can’t wait”
For abonnenter
Novo expands US partnership
For abonnenter
